Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01014585 · ClinicalTrials.gov registry record · Phase 4
Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 340
- Enrollment target
NCT01014585 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 340 participants.
The verdict
NCT01014585, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 340 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms following the discontinuation of milnacipran.
Interventions
- DRUG Placebo
- DRUG Milnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01014585
The ClinicalTrials.gov registry entry for NCT01014585 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01014585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01014585 about?
NCT01014585 is a clinical study titled "Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia". The purpose of this study is to evaluate the durability of effect of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment and to characterize the effects of milnacipran on multiple symptoms of fibromyalgia, as demonstrated by changes in symptoms followi...
What is the current status of trial NCT01014585?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 340 participants. The study started on 2009-11.
What interventions are being tested in trial NCT01014585?
The interventions under investigation include: Placebo (DRUG), Milnacipran (DRUG).
Who is sponsoring clinical trial NCT01014585?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.